- 专利标题： 2,3-dihydro-4H-1,3-benzoxazin-4-one derivatives as modulators of cholinergic muscarinic M1 receptor
-
申请号： US16394762申请日： 2019-04-25
-
公开(公告)号： US10899752B2公开(公告)日： 2021-01-26
- 发明人: Takahiro Sugimoto , Shinkichi Suzuki , Hiroki Sakamoto , Masami Yamada , Minoru Nakamura , Makoto Kamata , Kenichiro Shimokawa , Masataka Murakami , Jinichi Yonemori , Takuto Kojima
- 申请人： Takeda Pharmaceutical Company Limited
- 申请人地址： JP Osaka
- 专利权人： Takeda Pharmaceutical Company Limited
- 当前专利权人： Takeda Pharmaceutical Company Limited
- 当前专利权人地址： JP Osaka
- 代理机构： Hamre, Schumann, Mueller & Larson, P.C.
- 优先权： JP2015-129043 20150626,JP2015-206797 20151020
- 主分类号： C07D413/14
- IPC分类号： C07D413/14 ; C07D413/04 ; C07D413/06 ; C07D413/10 ; C07D417/06 ; C07D471/04 ; C07D491/107 ; C07D265/22 ; C07F7/02 ; A61P25/28 ; C07D417/10 ; C07F7/08
摘要：
The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity, which may be useful as a prophylactic or therapeutic drug for Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof: wherein each symbol is as defined in the attached DESCRIPTION.
公开/授权文献
信息查询
